These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27698397)

  • 1. Testicular cancer: Genetic determinants of cisplatin resistance.
    Thoma C
    Nat Rev Urol; 2016 Nov; 13(11):629. PubMed ID: 27698397
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular bases of platinum-resistance in testicular cancer].
    Germà-Lluch JR; Piulats JM
    Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of cisplatin-resistant testicular cancer cell lines established by two methods].
    Li B; Dong S; Fan Z; Wu X; Wu J; Tong X
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1755-9. PubMed ID: 26714911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
    Koster R; van Vugt MA; Timmer-Bosscha H; Gietema JA; de Jong S
    Expert Rev Mol Med; 2013 Sep; 15():e12. PubMed ID: 24074238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from testicular cancer: identification of cytoplasmic p21 as an Achilles' heel of cisplatin resistance.
    Koster R; de Jong S
    Cell Cycle; 2010 Dec; 9(24):4776-7. PubMed ID: 21150324
    [No Abstract]   [Full Text] [Related]  

  • 6. Role of Pannexin1 channels in the resistance of I-10 testicular cancer cells to cisplatin mediated by ATP/IP
    Wu D; Wu J; Liu H; Yu M; Tao L; Dong S; Tong X
    Biomed Pharmacother; 2017 Oct; 94():514-522. PubMed ID: 28780469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.
    Gerwing M; Jacobsen C; Dyshlovoy S; Hauschild J; Rohlfing T; Oing C; Venz S; Oldenburg J; Oechsle K; Bokemeyer C; von Amsberg G; Honecker F
    J Cancer Res Clin Oncol; 2016 Sep; 142(9):1979-94. PubMed ID: 27424191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin resistance in germ cell tumours: models and mechanisms.
    Jacobsen C; Honecker F
    Andrology; 2015 Jan; 3(1):111-21. PubMed ID: 25546083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
    Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
    J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells.
    Biersack B; Dietrich A; Zoldakova M; Kalinowski B; Paschke R; Schobert R; Mueller T
    J Inorg Biochem; 2011 Dec; 105(12):1630-7. PubMed ID: 22071088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro inhibited effect of gap junction composed of Cx43 in the invasion and metastasis of testicular cancer resistanced to cisplatin.
    Wu D; Li B; Liu H; Yuan M; Yu M; Tao L; Dong S; Tong X
    Biomed Pharmacother; 2018 Feb; 98():826-833. PubMed ID: 29571253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
    Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-line chemotherapy and novel agents for metastatic germ cell tumors.
    Veenstra CM; Vaughn DJ
    Hematol Oncol Clin North Am; 2011 Jun; 25(3):577-91, ix. PubMed ID: 21570610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.
    de Graaf TW; de Jong S; de Vries EG; Mulder NH
    Anticancer Res; 1997; 17(1A):369-75. PubMed ID: 9066679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular determinants of chemotherapy resistance in ovarian cancer.
    Cooley M; Fang P; Fang F; Nephew KP; Chien J
    Pharmacogenomics; 2015 Nov; 16(16):1763-7. PubMed ID: 26554863
    [No Abstract]   [Full Text] [Related]  

  • 17. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
    Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro.
    Eisenmann S; Voigt W; Müller T; Dempke W
    Anticancer Res; 2010 Nov; 30(11):4471-6. PubMed ID: 21115895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin resistance and opportunities for precision medicine.
    Amable L
    Pharmacol Res; 2016 Apr; 106():27-36. PubMed ID: 26804248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors.
    Varuni Kondagunta G; Bacik J; Schwartz L; Sheinfeld J; Bajorin D; Vuky J; Marion S; Mazumdar M; Bosl GJ; Motzer RJ
    Invest New Drugs; 2004 Apr; 22(2):177-9. PubMed ID: 14739666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.